Octagon Capital Advisors

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

ArriVent Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for cancer. The company aims to address unmet medical needs by leveraging its team's extensive experience in drug development. ArriVent is advancing its lead candidate, furmonertinib, along with a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. The company's initial emphasis is on solid tumors, reflecting its commitment to improving outcomes for cancer patients through differentiated medicines.

AnHeart Therapeutics is a clinical-stage biopharmaceutical company based in Hangzhou, China, founded in 2018. The company focuses on the discovery and development of innovative pharmaceutical products aimed at improving human health and the quality of life for cancer patients. AnHeart is dedicated to acquiring and commercializing novel therapies, with its lead product being AB-106, an oral small molecule inhibitor that selectively targets ROS1 and NTRK. Through its research and development efforts, AnHeart Therapeutics seeks to advance precision therapies that address the needs of individuals affected by cancer.

Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, the company specializes in developing mutant selective and isoform-specific drugs through non-conventional methods targeting established disease-related proteins. This approach aims to enhance drug efficacy and reduce the likelihood of resistance in patients, thereby improving therapeutic outcomes.

Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

ArriVent Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for cancer. The company aims to address unmet medical needs by leveraging its team's extensive experience in drug development. ArriVent is advancing its lead candidate, furmonertinib, along with a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. The company's initial emphasis is on solid tumors, reflecting its commitment to improving outcomes for cancer patients through differentiated medicines.

Biocytogen is a biotechnology company that specializes in developing gene-targeted animal models for life science research. Founded in 2008, with headquarters in Beijing, China, and additional facilities in the United States, Biocytogen offers a range of services including customized and off-the-shelf mouse models, as well as phenotype analysis across various biological areas such as immunology, neurology, and cancer. The company utilizes advanced gene-targeting platforms to create a variety of genetically modified animals, including humanized models and knockouts, to support preclinical studies. Biocytogen also provides pharmacology services related to tumor immunity and autoimmunity, and it markets its products online. With a commitment to integrating resources from both China and the United States, Biocytogen aims to be a leading global supplier of gene-targeted animal models.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.

Numab Therapeutics AG is a biotechnology company based in Wädenswil, Switzerland, founded in 2011. The company specializes in developing antibody-based therapeutics aimed at treating severe diseases, including cancer and chronic inflammation. Numab utilizes a unique plug-and-play platform that enhances the predictability of the drug discovery process, allowing for the efficient creation of multispecific biotherapeutics. Its research pipeline encompasses various therapeutic areas, including inflammatory bowel disease, immuno-oncology, autoimmunity, and inflammation.

Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.

Hummingbird Bioscience Pte. Ltd. is a biotechnology company based in Singapore, specializing in the development of antibody-based therapeutics for cancer. Founded in 2014, it leverages advances in systems biology and a proprietary rational antibody discovery platform to create innovative biotherapeutics. The company focuses on a diverse pipeline of drug candidates, which includes lead assets such as HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, both aimed at addressing significant unmet medical needs in oncology. Hummingbird Bioscience has established strategic collaborations with notable organizations such as Cancer Research UK and Amgen, and it has received a product development grant from the Cancer Prevention and Research Institute of Texas. The company's goal is to enhance treatment options for patients facing challenging cancer diagnoses through its cutting-edge research and development efforts.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.

Forge Biologics, Inc. is a contract development and manufacturing organization based in Columbus, Ohio, focused on developing and manufacturing gene therapies and genetic medicines. The company specializes in viral vector gene therapies aimed at treating genetic diseases, including a novel approach combining adeno-associated virus (AAV) with umbilical cord transplants for infantile Krabbe disease, a severe neurodegenerative condition. Founded in 2019, Forge Biologics partners with scientists, healthcare professionals, and biotech and pharmaceutical companies to facilitate the transition of gene therapy programs from preclinical development to clinical and commercial-scale production. By providing end-to-end capabilities, the company aims to accelerate the availability of transformative medicines for patients suffering from rare genetic disorders.

Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic therapies aimed at treating cancer. Immune-Onc Therapeutics focuses on the tumor microenvironment and immune suppressive pathways, utilizing advanced scientific insights to create novel immuno-oncology products. The company employs a targeted approach to develop first-in-class therapeutic antibodies that disarm immune suppression in tumors, thereby enhancing the immune response against cancer. Through its differentiated pipeline, Immune-Onc Therapeutics aims to provide new treatment options for cancer patients, addressing critical needs in the field of immunology and oncology.

Omega Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing genomic medicines aimed at curing diseases. Founded in 2016, the company utilizes its proprietary epigenomic programming platform to create Omega Epigenomic Controllers. These innovative controllers are designed to selectively modulate the activity of the human genome, allowing for precise tuning of gene expression to achieve therapeutic effects. By targeting specific cell types, Omega Therapeutics aims to transform human medicine through the direct control of genomic functions, offering potential solutions for a variety of diseases.

Nanjing Bioheng Biotech Co., Ltd., established in 2017 and based in Nanjing, China, is a clinical biopharmaceutical and biotechnology company that focuses on developing innovative immunotherapies and next-generation gene therapies for cancer and other diseases. The company offers advanced gene editing techniques and CAR-T therapies, and has created a robust production platform for plasmid, virus, and cell manufacturing. Bioheng has developed a GMP-grade clinical translational center and is recognized for its expertise in cell engineering and clinical applications. With a commitment to creating safer and more affordable cell therapy drugs, Bioheng aims to enhance patient access to effective treatments. The company has secured significant funding to further its research and development efforts, leveraging its extensive patent portfolio and industry experience to drive advancements in immunotherapy.

EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.

Aktis Oncology is a biotechnology company focused on developing targeted radiopharmaceuticals for the treatment of various solid tumor cancers. The company has created proprietary platforms that generate tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered to achieve high penetration into tumors and prolonged residence time, allowing for effective tumor elimination while reducing side effects associated with treatment. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing the precision of cancer treatment.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, specializing in the development of adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Founded in 2015, the company employs a unique STRucture Inspired DEsign approach that merges structural knowledge with accelerated evolution to create innovative AAV capsids. This technology is designed to evade neutralizing antibodies, thereby enhancing gene transfer efficiency. StrideBio's platform supports various gene therapy modalities, including gene addition, gene silencing, and gene editing, with applications across a range of rare genetic disorders.

Shanghai Hanyu Medical Technology Co., Ltd. specializes in the research and development of medical devices aimed at treating heart valve diseases. Established in 2016 and headquartered in Shanghai, with an additional office in Beijing, the company is recognized as one of the pioneering domestic firms in the development, production, and sale of transcatheter mitral valve repair devices. Hanyu Medical's flagship product, ValveClamp, is designed for minimally invasive interventions to address mitral valve regurgitation, enabling surgeons to close heart valves efficiently during procedures.

Arctic Vision (Shanghai) Biotechnology Co., Ltd. is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to meet the unmet clinical needs in ophthalmic diseases. The company has a portfolio of breakthrough technologies aimed at addressing various eye care challenges, including rare diseases through gene therapy. Established by prominent life sciences investors, Arctic Vision is led by a team of experienced professionals from the ophthalmic industry, bringing extensive expertise in research, development, and commercialization of eye care products. The company aims to deliver effective solutions not only in China but also across Asia and globally.

Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.

Cullgen Inc. is a biopharmaceutical company based in San Diego, California, established in 2018. The company focuses on developing innovative new chemical entities (NCEs) aimed at treating diseases that currently lack effective therapeutic options. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins. This approach is particularly significant for addressing cancer, inflammatory, and autoimmune diseases, including targets that have been deemed undruggable. By providing novel therapeutic strategies, Cullgen aims to enhance drug discovery and offer new avenues for treating debilitating conditions.

Vera Therapeutics is engaged in the development of innovative gene editing solutions aimed at curing genetic diseases, particularly sickle cell disease and cystic fibrosis. The company utilizes a proprietary triplex gene editing platform to create a pipeline of therapeutic products targeting high-penetrance disease genes. Founded in 2016 and based in South San Francisco, California, Vera Therapeutics is dedicated to alleviating and potentially curing genetic disorders in affected patients.

Immvira Co., Ltd. is a biopharmaceutical company based in Shenzhen, China, established in May 2015 by a team of renowned professors from various prestigious universities. The company specializes in the development of innovative anti-cancer therapies that utilize genetically engineered viruses. These therapies are designed to target cancer cells specifically and are enhanced by cancer-specific immune factors or chemotherapeutic agents. Immvira's product offerings include oncolytic herpes simplex viruses (oHSV) that encode interleukin-12 and anti-PD-1 antibodies, which can be delivered directly into tumor masses or in combination with systemic immune modulators. The company also explores auxiliary therapies and engineered viruses that can infect tumor cells with unique surface receptors.

Medbanks Network Technology Co. Ltd., founded in 2014 and headquartered in Beijing, China, provides data processing services tailored for the healthcare industry. The company specializes in developing a multi-center database that aggregates and analyzes data reflecting China's patient population. Additionally, Medbanks creates an oncology database that incorporates clinical and professional medical services based on information collected from hospitals. This focus on data management and analysis aims to enhance healthcare services and research in China.

Zylox Medical Device Co. was founded in the beautiful city of Hangzhou in 2012 by a group of highly skillful and experienced returnees from the US and Europe. They have on average 5-20 years of working experiences in various functional areas such as research and development, management, and manufacturing in leading device makers including Johnson & Johnson, Medtronic, and Abbott before returning to China. Since its inception, Zylox has developed an increasingly rich product pipeline of interventional and implantable peripheral vascular devices such as PTA balloons, PTA drug-coated Balloons (PTA DCB), superficial femoral artery (SFA) stent, drug-eluting SFA stent, and other vascular accessories. Zylox strives to continuously innovate and provide patients with superior quality medical devices.

Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

Taysha Gene Therapies is a company focused on developing adeno-associated virus (AAV) based gene therapies aimed at treating monogenic diseases of the central nervous system. Founded in 2019 and based in Dallas, Texas, the company is advancing several therapeutic candidates, including TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha Gene Therapies collaborates with The University of Texas Southwestern Medical Center to enhance the development and commercialization of its innovative treatments, with a mission to eradicate severe and life-threatening CNS diseases through curative gene therapies. The company's expertise in drug development and its partnership with a leading gene therapy program enable it to effectively progress its pipeline of potential therapies.

4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing targeted gene therapy products using evolved adeno-associated virus vectors. The company has a diverse portfolio focusing on three main therapeutic areas: ophthalmology, cardiology, and pulmonology. Key product candidates include 4D-125, currently in a Phase I/II clinical trial for treating X-linked retinitis pigmentosa; 4D-110, in a Phase I trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is developing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. The company aims to address unmet medical needs through its innovative gene therapies.

Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.

MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

RemeGen Co., Ltd. is a biopharmaceutical company based in Yantai, China, that focuses on the discovery, development, and commercialization of biologics aimed at addressing unmet medical needs in autoimmune, oncology, and ophthalmic diseases. Established in 2008, RemeGen specializes in innovative biologics, including monoclonal antibodies and antibody-drug conjugates. Its key products under development include Telitacicept, which targets autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, and Disitamab Vedotin for various cancers. The company is also advancing other candidates like RC28 and RC88 for retinal conditions, alongside several pre-clinical products aimed at treating solid tumors. RemeGen operates primarily in China but also maintains laboratories and offices in Beijing and California, emphasizing its commitment to fulfilling the medical needs of patients with life-threatening conditions.

Peijia Medical Limited specializes in the research, development, production, and sales of interventional medical devices aimed at treating structural heart and neurovascular diseases. Founded in 2012 and based in Suzhou, China, the company offers a range of transcatheter aortic valve replacement (TAVR) products, including its TaurusOne, TaurusElite, and TaurusNXT systems. Additionally, Peijia is advancing the development of transcatheter mitral and tricuspid valve replacement devices, as well as ancillary products such as lithotripsy and balloon aortic valvuloplasty catheters. The company also produces neurointerventional products, including stent retrievers and various catheter types designed for complex vascular procedures. With a focus on both transcatheter valve therapeutic and neurointerventional markets, Peijia Medical operates from a modern facility that combines advanced technology with an aesthetically pleasing design, reflecting its commitment to innovation in the medical device industry.

Ocumension Therapeutics is a Shanghai-based company that develops and manufactures ophthalmic pharmaceutical preparations, focusing on therapies for conditions such as blepharitis, allergic conjunctivitis, dry eye, cataract, myopia, uveitis, and glaucoma. Founded in 2017, the company aims to address significant unmet medical needs in the ophthalmic field in China by providing innovative solutions. Ocumension Therapeutics has established a comprehensive platform that integrates specialized capabilities across the entire development cycle of ophthalmic drugs, from research and development to manufacturing and commercialization. This strategic approach positions the company to achieve leadership in the ophthalmology sector in China, leveraging its first-mover advantage to stay ahead of potential competitors. Additionally, Ocumension operates a location in Cambridge, Massachusetts, enhancing its international presence.